Zacks Investment Research upgraded shares of Corindus Vascular Robotics Inc (NYSEMKT:CVRS) from a hold rating to a buy rating in a research note published on Thursday morning. The firm currently has $1.50 price target on the stock.
According to Zacks, “Corindus Vascular Robotics, Inc. is involved in designing, manufacturing and selling precision vascular robotic-assisted systems for interventional vascular procedures. The Company’s product includes CorPath 200 system a vascular robotic system which provide stent placement in percutaneous coronary intervention procedures. Corindus Vascular Robotics, Inc. is based in Waltham, Massachusetts. “
Separately, B. Riley reissued a buy rating and issued a $3.00 target price on shares of Corindus Vascular Robotics in a research note on Tuesday, March 14th.
Corindus Vascular Robotics (NYSEMKT:CVRS) opened at 1.41 on Thursday. The stock has a 50 day moving average of $0.79 and a 200-day moving average of $0.86. The firm’s market cap is $167.83 million. Corindus Vascular Robotics has a 52 week low of $0.40 and a 52 week high of $1.80.
Your IP Address:
In related news, major shareholder Healthcor Management, L.P. acquired 7,557,436 shares of Corindus Vascular Robotics stock in a transaction on Tuesday, February 28th. The stock was purchased at an average cost of $0.66 per share, with a total value of $4,987,907.76. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
An institutional investor recently raised its position in Corindus Vascular Robotics stock. State Street Corp increased its position in Corindus Vascular Robotics Inc (NYSEMKT:CVRS) by 0.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 566,932 shares of the company’s stock after buying an additional 4,847 shares during the period. State Street Corp owned about 0.48% of Corindus Vascular Robotics worth $395,000 at the end of the most recent reporting period.
Corindus Vascular Robotics Company Profile
Corindus Vascular Robotics, Inc designs, manufactures and sells precision vascular robotic-assisted systems for use in interventional vascular procedures (the CorPath System). The Company operates through the development, marketing and sales of robotic-assisted vascular interventions segment. The Company’s product, the CorPath 200 System, is a vascular robotic system, which is engaged in stent placement in percutaneous coronary intervention (PCI) procedures.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Corindus Vascular Robotics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics Inc and related companies with MarketBeat.com's FREE daily email newsletter.